Gastrointestinal cancer
Conditions
Interventions
Observation group:None
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Study participants voluntarily participate in this study, sign an informed consent form, and have good compliance; 2. Age> = 18 years old; 3. Received immunotherapy in the first line and has been assessed by the investigator to be immune to drug resistance; 4. Have at least 1 measurable lesion (according to RECIST 1.1 criteria); 5. ECOG score 0-2 points; 6. Expected survival >=12 weeks; 7. Study participants of childbearing potential: Must agree to abstinence or use a reliable, effective method of contraception from the time of signing the informed consent form until at least 90 days after the last dose of study drug. and female study participants must have a negative serum or urine HCG test;
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to apalolitovorelimab and its excipients; 2. Previous immune-related adverse reactions of >=3 grades; 3. Patients who are currently participating in other interventional clinical studies; 4. Pregnant and lactating females; 5. Has a severe concomitant illness or other comorbid disease that would interfere with the planned treatment, or any other condition that, in the opinion of the investigator, the patient is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Disease control rate;Duration of remission; | — |
Countries
China
Contacts
Public ContactLiu Ying
Henan Cancer Hospital
Outcome results
None listed